ASENAPINE

ASENAPINE was reported 8671 times

ASENAPINE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DOPAMINE SUPERSENSITIVITY PSYCHOSIS 4 0.2500
1 VENTRICULAR REMODELING 1 0.2000
2 THERMAL BURNS OF EYE 12 0.0531
3 CARDIOMETABOLIC SYNDROME 4 0.0421
4 MAGICAL THINKING 1 0.0385
5 THYROIDITIS ACUTE 5 0.0350
6 MYOCARDITIS BACTERIAL 1 0.0303
7 MANIC SYMPTOM 4 0.0238
8 PANCREATIC STEATOSIS 4 0.0147
9 VASCULAR DEMENTIA 12 0.0137
10 SOCIAL ANXIETY DISORDER 8 0.0122
11 MICROCYTOSIS 3 0.0121
12 SELECTIVE EATING DISORDER 11 0.0121
13 DYSDIADOCHOKINESIS 2 0.0117
14 TRANSFERRIN DECREASED 2 0.0098
15 DISSOCIATIVE IDENTITY DISORDER 2 0.0095
16 CATAPLEXY 13 0.0092
17 VENTRICULAR DYSSYNCHRONY 1 0.0090
18 LABELLED DRUG-DRUG INTERACTION ISSUE 12 0.0083
19 PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION 1 0.0080
20 MYASTHENIC SYNDROME 6 0.0078
21 PRODUCT INEFFECTIVE 6 0.0076
22 DELUSION OF REFERENCE 1 0.0072
23 GLUCOSE URINE 1 0.0067
24 PLEUROTHOTONUS 6 0.0066
25 PULMONARY VALVE INCOMPETENCE 9 0.0062
26 VISCERAL CONGESTION 3 0.0059
27 NEAR DROWNING 1 0.0057
28 COGWHEEL RIGIDITY 6 0.0057
29 PICA 1 0.0056
30 THERAPEUTIC PRODUCT EFFECTIVE FOR UNAPPROVED INDICATION 2 0.0054
31 QRS AXIS ABNORMAL 4 0.0052
32 NEPHROGENIC DIABETES INSIPIDUS 6 0.0052
33 MYOCARDITIS 58 0.0051
34 DYSMETRIA 3 0.0050
35 SPLENIC CYST 1 0.0048
36 OCULOGYRIC CRISIS 10 0.0047
37 ZINC DEFICIENCY 1 0.0047
38 LEFT VENTRICULAR END-DIASTOLIC PRESSURE INCREASED 1 0.0046
39 PRODUCT SOLUBILITY ABNORMAL 23 0.0046
40 MUCOCUTANEOUS ULCERATION 1 0.0044
41 CAMPTOCORMIA 1 0.0042
42 ANOSOGNOSIA 3 0.0039
43 MYOCARDIAL DEPRESSION 1 0.0039
44 CULTURE STOOL POSITIVE 1 0.0036
45 HEAD TITUBATION 5 0.0036
46 ADMINISTRATION SITE ERYTHEMA 1 0.0035
47 HYPEROSMOLAR STATE 1 0.0035
48 BURN ORAL CAVITY 2 0.0035
49 MICROCYTIC ANAEMIA 7 0.0034
50 SPASMODIC DYSPHONIA 1 0.0033
51 CEREBRAL ATROPHY 13 0.0033
52 TONGUE SPASM 1 0.0032
53 ANTICHOLINERGIC SYNDROME 5 0.0031
54 ELECTROCARDIOGRAM QRS COMPLEX ABNORMAL 1 0.0031
55 POLYHYDRAMNIOS 3 0.0029
56 PSYCHOTIC SYMPTOM 6 0.0029
57 ANTIPSYCHOTIC DRUG LEVEL BELOW THERAPEUTIC 2 0.0029
58 PANCREATIC NECROSIS 1 0.0029
59 CIRCUMORAL OEDEMA 1 0.0029
60 TONGUE EXFOLIATION 1 0.0028
61 EYE SYMPTOM 1 0.0028
62 SEDATION COMPLICATION 7 0.0027
63 OSMOTIC DEMYELINATION SYNDROME 2 0.0027
64 ADMINISTRATION SITE REACTION 1 0.0026
65 ELECTROCARDIOGRAM T WAVE ABNORMAL 4 0.0026
66 MASKED FACIES 1 0.0025
67 TONGUE ERYTHEMA 2 0.0024
68 APPLICATION SITE LACERATION 1 0.0024
69 DELUSIONAL PERCEPTION 1 0.0024
70 CONGESTIVE CARDIOMYOPATHY 10 0.0024
71 SWEAT GLAND DISORDER 1 0.0024
72 PYRAMIDAL TRACT SYNDROME 1 0.0024
73 BLOOD PROLACTIN ABNORMAL 2 0.0023
74 FEELINGS OF WORTHLESSNESS 3 0.0023
75 EMBOLIC STROKE 8 0.0023
76 ANTIPSYCHOTIC DRUG LEVEL ABOVE THERAPEUTIC 2 0.0022
77 DELUSION OF GRANDEUR 1 0.0022
78 ABULIA 2 0.0022
79 NEUROLOGICAL EXAMINATION ABNORMAL 1 0.0021
80 DRUG DISPENSED TO WRONG PATIENT 2 0.0021
81 WEIGHT ABNORMAL 5 0.0021
82 NEGATIVE THOUGHTS 6 0.0020
83 EXCESSIVE EYE BLINKING 3 0.0020
84 PRODUCT BLISTER PACKAGING ISSUE 2 0.0019
85 METABOLIC SYNDROME 3 0.0018
86 BIPOLAR I DISORDER 4 0.0018
87 BLOOD INSULIN INCREASED 1 0.0018
88 FACIAL SPASM 2 0.0018
89 REPETITIVE SPEECH 1 0.0018
90 POLYDIPSIA 7 0.0018
91 INTENTION TREMOR 1 0.0018
92 PROTRUSION TONGUE 1 0.0017
93 SUTURE INSERTION 1 0.0017
94 AKATHISIA 23 0.0017
95 MALE SEXUAL DYSFUNCTION 1 0.0017
96 PARKINSONISM 16 0.0016
97 NEURODEGENERATIVE DISORDER 1 0.0016
98 ACUTE PSYCHOSIS 4 0.0016
99 THERAPEUTIC PRODUCT INEFFECTIVE 6 0.0016
100 RESTING TREMOR 1 0.0015
101 CHANGE IN SEIZURE PRESENTATION 1 0.0015
102 PSYCHIATRIC DECOMPENSATION 3 0.0015
103 SEDATION 40 0.0015
104 NEUROLEPTIC MALIGNANT SYNDROME 18 0.0015
105 GINGIVAL DISCOMFORT 1 0.0015
106 HALLUCINATION, AUDITORY 24 0.0015
107 MANIA 24 0.0015
108 IMMUNOGLOBULINS DECREASED 2 0.0015
109 ANGULAR CHEILITIS 1 0.0014
110 SUSPICIOUSNESS 1 0.0014
111 APPLICATION SITE ULCER 1 0.0014
112 SINUS TACHYCARDIA 20 0.0014
113 SCHIZOPHRENIA 17 0.0014
114 SYMPTOM MASKED 1 0.0014
115 AUTONOMIC NERVOUS SYSTEM IMBALANCE 4 0.0014
116 ELECTROCARDIOGRAM T WAVE INVERSION 3 0.0014
117 CENTRAL OBESITY 1 0.0014
118 SEROTONIN SYNDROME 26 0.0014
119 APRAXIA 2 0.0013
120 DYSTONIA 26 0.0013
121 MULTIPLE DRUG THERAPY 1 0.0013
122 ORAL MUCOSAL EXFOLIATION 2 0.0013
123 ORAL MUCOSAL ERYTHEMA 2 0.0013
124 DISTURBANCE IN SOCIAL BEHAVIOUR 3 0.0013
125 TRICUSPID VALVE INCOMPETENCE 10 0.0013
126 DISINHIBITION 2 0.0012
127 CIRCADIAN RHYTHM SLEEP DISORDER 1 0.0012
128 ADRENAL MASS 1 0.0012
129 LEFT VENTRICULAR DYSFUNCTION 8 0.0012
130 SELF-INJURIOUS IDEATION 5 0.0012
131 BUNDLE BRANCH BLOCK LEFT 5 0.0012
132 TONGUE MOVEMENT DISTURBANCE 1 0.0012
133 RESPIRATION ABNORMAL 8 0.0012
134 SERUM FERRITIN DECREASED 2 0.0012
135 SELF-DESTRUCTIVE BEHAVIOUR 1 0.0011
136 ADRENOCORTICOTROPIC HORMONE DEFICIENCY 1 0.0011
137 DRUG DETOXIFICATION 1 0.0011
138 PRODUCT RESIDUE PRESENT 6 0.0011
139 CATARRH 1 0.0011
140 SALIVARY HYPERSECRETION 11 0.0011
141 DELUSION 17 0.0011
142 BUNDLE BRANCH BLOCK RIGHT 5 0.0011
143 EXTENSOR PLANTAR RESPONSE 1 0.0011
144 OTOTOXICITY 2 0.0011
145 APPLICATION SITE DERMATITIS 1 0.0011
146 PSYCHOMOTOR RETARDATION 3 0.0011
147 INTRACRANIAL MASS 1 0.0011
148 PRODUCT AFTER TASTE 1 0.0010
149 EYELID OEDEMA 12 0.0010
150 CONVERSION DISORDER 2 0.0010
151 PROSTATOMEGALY 4 0.0010
152 MUCOSAL DISORDER 1 0.0010
153 HYPERNATRAEMIA 5 0.0010
154 EMBOLISM VENOUS 3 0.0010
155 AUTONOMIC NEUROPATHY 1 0.0010
156 BREAST NEOPLASM 1 0.0010
157 CONSCIOUSNESS FLUCTUATING 1 0.0010
158 CATATONIA 5 0.0010
159 SYSTOLIC DYSFUNCTION 1 0.0009
160 TONGUE DISCOMFORT 4 0.0009
161 VENTRICULAR HYPOKINESIA 3 0.0009
162 BINGE EATING 1 0.0009
163 PRODUCT NAME CONFUSION 1 0.0009
164 HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME 1 0.0009
165 GASTROINTESTINAL HYPOMOTILITY 2 0.0009
166 EXTRAPYRAMIDAL DISORDER 22 0.0009
167 DRUG EFFECT VARIABLE 1 0.0009
168 COMPLETED SUICIDE 73 0.0009
169 PRIAPISM 3 0.0009
170 DISTRACTIBILITY 1 0.0009
171 IRON DEFICIENCY ANAEMIA 8 0.0009
172 MORBID THOUGHTS 1 0.0009
173 SUSPECTED SUICIDE 4 0.0009
174 SEXUAL DYSFUNCTION 10 0.0009
175 LOGORRHOEA 3 0.0009
176 LABILE BLOOD PRESSURE 1 0.0008
177 MAJOR DEPRESSION 6 0.0008
178 MONOCYTE COUNT DECREASED 1 0.0008
179 PARANOIA 14 0.0008
180 POST-ACUTE COVID-19 SYNDROME 1 0.0008
181 BLOOD UREA DECREASED 1 0.0008
182 APPLICATION SITE IRRITATION 10 0.0008
183 INTRADUCTAL PROLIFERATIVE BREAST LESION 1 0.0008
184 NEUTROPHIL PERCENTAGE INCREASED 1 0.0008
185 EXPOSURE VIA INGESTION 2 0.0008
186 TROPONIN T INCREASED 1 0.0008
187 GLUCOSE URINE PRESENT 1 0.0008
188 TONGUE OEDEMA 3 0.0008
189 LEFT ATRIAL DILATATION 1 0.0008
190 BLOOD CREATINE PHOSPHOKINASE MB INCREASED 1 0.0008
191 FEELING GUILTY 1 0.0008
192 LYMPHOCYTE PERCENTAGE DECREASED 1 0.0007
193 ENURESIS 3 0.0007
194 BRADYPNOEA 2 0.0007
195 BODY MASS INDEX INCREASED 1 0.0007
196 CARBON DIOXIDE INCREASED 1 0.0007
197 URETERIC OBSTRUCTION 1 0.0007
198 CLONUS 2 0.0007
199 ASPIRATION 8 0.0007
200 EYE MOVEMENT DISORDER 5 0.0007
201 SELF-MEDICATION 3 0.0007
202 ACCIDENTAL POISONING 1 0.0007
203 APPLICATION SITE INFLAMMATION 1 0.0007
204 PERIODONTAL DISEASE 1 0.0007
205 ANTIPSYCHOTIC DRUG LEVEL INCREASED 2 0.0007
206 ANTICONVULSANT DRUG LEVEL DECREASED 1 0.0007
207 MITRAL VALVE INCOMPETENCE 8 0.0007
208 AUDITORY DISORDER 1 0.0007
209 NUCLEAR MAGNETIC RESONANCE IMAGING BRAIN ABNORMAL 1 0.0007
210 JUDGEMENT IMPAIRED 1 0.0007
211 GENERALISED ANXIETY DISORDER 1 0.0007
212 BRADYKINESIA 4 0.0007
213 CREPITATIONS 2 0.0007
214 MENTAL FATIGUE 1 0.0007
215 EPICONDYLITIS 1 0.0007
216 SECONDARY ADRENOCORTICAL INSUFFICIENCY 1 0.0007
217 MEAN CELL VOLUME DECREASED 1 0.0006
218 CONJUNCTIVITIS 12 0.0006
219 VIOLENCE-RELATED SYMPTOM 1 0.0006
220 POLYCYSTIC OVARIES 1 0.0006
221 BLOOD PROLACTIN INCREASED 3 0.0006
222 ATRIAL FLUTTER 5 0.0006
223 METABOLIC ALKALOSIS 1 0.0006
224 GALACTORRHOEA 4 0.0006
225 SUBSTANCE ABUSE 5 0.0006
226 ASPHYXIA 5 0.0006
227 ELECTROCARDIOGRAM QT PROLONGED 22 0.0006
228 SEBORRHOEIC DERMATITIS 1 0.0006
229 ILLUSION 1 0.0006
230 QUADRIPARESIS 1 0.0006
231 TONGUE ULCERATION 2 0.0006
232 DYSLIPIDAEMIA 3 0.0006
233 GAZE PALSY 1 0.0006
234 MUSCLE RIGIDITY 7 0.0006
235 MENTAL IMPAIRMENT 14 0.0006
236 TACHYPHRENIA 2 0.0006
237 PSYCHOTIC DISORDER 17 0.0006
238 LACK OF INJECTION SITE ROTATION 1 0.0006
239 ALOPECIA AREATA 1 0.0006
240 HALLUCINATION, VISUAL 12 0.0006
241 FACIAL PARESIS 2 0.0006
242 GLOSSITIS 2 0.0006
243 SCHIZOAFFECTIVE DISORDER 1 0.0006
244 APPLICATION SITE DISCOMFORT 1 0.0006
245 OBSESSIVE THOUGHTS 1 0.0006
246 DRUG INTERACTION 87 0.0005
247 HYPERSEXUALITY 1 0.0005
248 MEAN CELL HAEMOGLOBIN DECREASED 1 0.0005
249 DRUG RESISTANCE 14 0.0005
250 CHOKING SENSATION 3 0.0005
251 HYPOMANIA 2 0.0005
252 HOMICIDE 1 0.0005
253 DISORGANISED SPEECH 1 0.0005
254 HYPERTRICHOSIS 1 0.0005
255 DIFFUSE ALOPECIA 1 0.0005
256 PRODUCT SUBSTITUTION ISSUE 31 0.0005
257 ACCIDENTAL DEATH 1 0.0005
258 BLOOD CHOLESTEROL DECREASED 1 0.0005
259 TRAUMATIC HAEMORRHAGE 1 0.0005
260 PROTEIN TOTAL DECREASED 2 0.0005
261 SNORING 2 0.0005
262 BLOOD BICARBONATE DECREASED 1 0.0005
263 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 5 0.0005
264 LYMPHADENOPATHY MEDIASTINAL 1 0.0005
265 METABOLIC DISORDER 3 0.0005
266 ADRENOCORTICAL INSUFFICIENCY ACUTE 1 0.0005
267 OBSESSIVE-COMPULSIVE DISORDER 4 0.0005
268 HYPOPHYSITIS 1 0.0005
269 SMALL INTESTINAL HAEMORRHAGE 1 0.0005
270 CHANGE OF BOWEL HABIT 1 0.0005
271 THINKING ABNORMAL 9 0.0005
272 PHYSICAL ASSAULT 1 0.0005
273 DILATATION VENTRICULAR 1 0.0005
274 AORTIC VALVE INCOMPETENCE 2 0.0005
275 DEREALISATION 1 0.0005
276 HYPOAESTHESIA ORAL 7 0.0005
277 DEAFNESS 12 0.0005
278 OLIGOMENORRHOEA 1 0.0005
279 PULMONARY CONGESTION 6 0.0005
280 PRODUCT FORMULATION ISSUE 3 0.0005
281 SOPOR 6 0.0005
282 BLOOD CREATINE INCREASED 2 0.0005
283 POST-TRAUMATIC STRESS DISORDER 3 0.0004
284 SUBSTANCE-INDUCED PSYCHOTIC DISORDER 1 0.0004
285 PRODUCT TASTE ABNORMAL 6 0.0004
286 MYOCARDIAL ISCHAEMIA 5 0.0004
287 ISCHAEMIA 2 0.0004
288 EOSINOPHIL COUNT DECREASED 1 0.0004
289 URINARY HESITATION 1 0.0004
290 PANIC REACTION 3 0.0004
291 LIVER FUNCTION TEST ABNORMAL 12 0.0004
292 PENIS DISORDER 1 0.0004
293 TACHYARRHYTHMIA 1 0.0004
294 TOXICITY TO VARIOUS AGENTS 67 0.0004
295 VASODILATATION 1 0.0004
296 EUPHORIC MOOD 4 0.0004
297 MEDICATION RESIDUE 1 0.0004
298 BLOOD CHLORIDE DECREASED 1 0.0004
299 TRISMUS 2 0.0004
300 LEUKOCYTOSIS 7 0.0004
301 RHABDOMYOLYSIS 16 0.0004
302 PRODUCT PACKAGING DIFFICULT TO OPEN 1 0.0004
303 RESTLESSNESS 14 0.0004
304 PERSONALITY DISORDER 1 0.0004
305 BLOOD LACTIC ACID INCREASED 2 0.0004
306 NYSTAGMUS 2 0.0004
307 DYSKINESIA 15 0.0004
308 ORAL DISCOMFORT 5 0.0004
309 DEPRESSED MOOD 19 0.0004
310 EJACULATION DISORDER 1 0.0004
311 SUICIDAL IDEATION 32 0.0003
312 EXERCISE TOLERANCE DECREASED 2 0.0003
313 HYPERTHYROIDISM 5 0.0003
314 HYPERVENTILATION 2 0.0003
315 HYPERTRIGLYCERIDAEMIA 2 0.0003
316 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 10 0.0003
317 STRIDOR 1 0.0003
318 CARDIOMYOPATHY 5 0.0003
319 DISEASE RECURRENCE 16 0.0003
320 CARDIO-RESPIRATORY ARREST 14 0.0003
321 DIASTOLIC DYSFUNCTION 1 0.0003
322 MULTIPLE-DRUG RESISTANCE 1 0.0003
323 BLOOD CREATININE DECREASED 1 0.0003
324 TARDIVE DYSKINESIA 9 0.0003
325 THERAPEUTIC RESPONSE CHANGED 2 0.0003
326 EXPOSURE TO TOXIC AGENT 1 0.0003
327 HYPERPROLACTINAEMIA 2 0.0003
328 POSTURE ABNORMAL 1 0.0003
329 APPLICATION SITE ERYTHEMA 8 0.0003
330 CHOLELITHIASIS 10 0.0003
331 SOMNAMBULISM 2 0.0003
332 DYSGRAPHIA 2 0.0003
333 ELECTROCARDIOGRAM ST SEGMENT ELEVATION 1 0.0003
334 ANXIETY DISORDER 1 0.0003
335 WRONG PRODUCT ADMINISTERED 2 0.0003
336 APPLICATION SITE DRYNESS 1 0.0003
337 SUDDEN CARDIAC DEATH 1 0.0003
338 APPLICATION SITE RASH 4 0.0003
339 TREATMENT FAILURE 24 0.0003
340 DROOLING 2 0.0003
341 DELIRIUM 10 0.0003
342 FORMICATION 2 0.0003
343 ORTHOSTATIC HYPOTENSION 5 0.0003
344 HYPERREFLEXIA 1 0.0003
345 TYPE I HYPERSENSITIVITY 1 0.0003
346 DEPRESSIVE SYMPTOM 1 0.0003
347 IMPAIRED QUALITY OF LIFE 4 0.0003
348 ABNORMAL BEHAVIOUR 11 0.0003
349 MONOCYTE COUNT INCREASED 1 0.0003
350 CUTANEOUS VASCULITIS 1 0.0003
351 BLOOD PHOSPHORUS DECREASED 1 0.0003
352 VENTRICULAR ARRHYTHMIA 1 0.0003
353 ORAL DISORDER 2 0.0003
354 ALCOHOL USE 1 0.0003
355 GLOSSODYNIA 6 0.0003
356 SUICIDE ATTEMPT 16 0.0003
357 TROPONIN INCREASED 2 0.0003
358 HYPERTHERMIA 2 0.0003
359 TINNITUS 12 0.0003
360 DISSOCIATION 2 0.0003
361 GINGIVAL DISORDER 1 0.0003
362 PANIC DISORDER 1 0.0003
363 OEDEMA 14 0.0003
364 CELLULITIS 13 0.0003
365 THERAPEUTIC PRODUCT EFFECT VARIABLE 1 0.0003
366 TREATMENT NONCOMPLIANCE 14 0.0003
367 ELECTROCARDIOGRAM ABNORMAL 2 0.0003
368 AFFECTIVE DISORDER 2 0.0003
369 RESPIRATORY ACIDOSIS 1 0.0003
370 RESPIRATORY ARREST 7 0.0003
371 PRODUCT USE COMPLAINT 4 0.0003
372 PRODUCT PHYSICAL ISSUE 5 0.0002
373 INTENTIONAL SELF-INJURY 5 0.0002
374 HYPERSOMNIA 7 0.0002
375 APPLICATION SITE EXFOLIATION 1 0.0002
376 RED CELL DISTRIBUTION WIDTH INCREASED 1 0.0002
377 AGGRESSION 12 0.0002
378 LIP OEDEMA 1 0.0002
379 AGITATION 17 0.0002
380 DEPRESSED LEVEL OF CONSCIOUSNESS 9 0.0002
381 HEPATOTOXICITY 5 0.0002
382 MYOSITIS 2 0.0002
383 URINE ABNORMALITY 1 0.0002
384 METABOLIC ACIDOSIS 7 0.0002
385 DRUG LEVEL ABOVE THERAPEUTIC 1 0.0002
386 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 4 0.0002
387 CARDIAC ARREST 18 0.0002
388 MUSCLE TWITCHING 5 0.0002
389 PERSONALITY CHANGE 2 0.0002
390 FEELING OF DESPAIR 1 0.0002
391 TUBULOINTERSTITIAL NEPHRITIS 4 0.0002
392 BLOOD SODIUM DECREASED 4 0.0002
393 LEUKAEMIA 2 0.0002
394 SPINAL COLUMN STENOSIS 1 0.0002
395 INCREASED APPETITE 4 0.0002
396 FAECAL INCONTINENCE 1 0.0002
397 HYPERCHOLESTEROLAEMIA 2 0.0002
398 EXPIRED DRUG ADMINISTERED 1 0.0002
399 ABDOMINAL TENDERNESS 1 0.0002
400 HYPERAMMONAEMIA 1 0.0002
401 FLUID INTAKE REDUCED 1 0.0002
402 SWELLING FACE 13 0.0002
403 PRODUCT ADMINISTRATION ERROR 4 0.0002
404 DRUG TOLERANCE 1 0.0002
405 HYPOTHERMIA 2 0.0002
406 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 14 0.0002
407 DEVICE ADHESION ISSUE 3 0.0002
408 NEUTROPHIL COUNT INCREASED 2 0.0002
409 HYPONATRAEMIA 11 0.0002
410 INITIAL INSOMNIA 2 0.0002
411 INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION 2 0.0002
412 UNRESPONSIVE TO STIMULI 5 0.0002
413 ACCIDENTAL OVERDOSE 7 0.0002
414 SPEECH DISORDER 10 0.0002
415 PREMATURE DELIVERY 3 0.0002
416 LEARNING DISABILITY 1 0.0002
417 SENSORY DISTURBANCE 3 0.0002
418 GASTROINTESTINAL MOTILITY DISORDER 1 0.0002
419 POOR QUALITY SLEEP 4 0.0002
420 BEHAVIOUR DISORDER 1 0.0002
421 ALTERED STATE OF CONSCIOUSNESS 4 0.0002
422 BIPOLAR DISORDER 2 0.0002
423 TIC 1 0.0002
424 MOOD ALTERED 5 0.0002
425 IRRITABILITY 11 0.0002
426 FAECALOMA 1 0.0002
427 AUTISM SPECTRUM DISORDER 1 0.0002
428 DRUG LEVEL BELOW THERAPEUTIC 1 0.0002
429 DRUG LEVEL INCREASED 3 0.0002
430 PSYCHOMOTOR HYPERACTIVITY 3 0.0002
431 MENTAL STATUS CHANGES 5 0.0002
432 LEUKOPENIA 9 0.0002
433 IMPAIRED DRIVING ABILITY 2 0.0002
434 NEUTROPHILIA 1 0.0002
435 GRANULOCYTOPENIA 1 0.0002
436 CHOLECYSTECTOMY 2 0.0002
437 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 3 0.0002
438 MOUTH SWELLING 1 0.0002
439 RALES 1 0.0002
440 AMENORRHOEA 3 0.0002
441 TACHYCARDIA 15 0.0002
442 BLOOD IRON DECREASED 2 0.0002
443 DRUG ABUSE 14 0.0002
444 ODYNOPHAGIA 1 0.0002
445 APHASIA 5 0.0002
446 DRUG DIVERSION 1 0.0002
447 AGRANULOCYTOSIS 3 0.0002
448 SWOLLEN TONGUE 5 0.0002
449 SOMNOLENCE 32 0.0002
450 GLYCOSYLATED HAEMOGLOBIN INCREASED 4 0.0002
451 DEPRESSION 36 0.0002
452 SCREAMING 1 0.0002
453 PULMONARY OEDEMA 7 0.0002
454 BRADYPHRENIA 1 0.0002
455 DISORIENTATION 6 0.0002
456 COLITIS ISCHAEMIC 1 0.0001
457 NEUTROPHIL COUNT DECREASED 6 0.0001
458 HALLUCINATION 11 0.0001
459 RESPIRATORY DISTRESS 4 0.0001
460 POLLAKIURIA 6 0.0001
461 MOUTH ULCERATION 3 0.0001
462 APPLICATION SITE REACTION 1 0.0001
463 DIVERTICULUM 1 0.0001
464 HYPOTENSION 28 0.0001
465 BLOOD CREATINE PHOSPHOKINASE INCREASED 4 0.0001
466 PARAESTHESIA ORAL 2 0.0001
467 WEIGHT INCREASED 31 0.0001
468 TONGUE DISORDER 1 0.0001
469 ACUTE KIDNEY INJURY 21 0.0001
470 APATHY 2 0.0001
471 DYSSTASIA 4 0.0001
472 PSYCHIATRIC SYMPTOM 1 0.0001
473 GAMMA-GLUTAMYLTRANSFERASE INCREASED 3 0.0001
474 CEREBRAL DISORDER 1 0.0001
475 DYSARTHRIA 5 0.0001
476 APPLICATION SITE PRURITUS 3 0.0001
477 INSURANCE ISSUE 2 0.0001
478 BOWEL MOVEMENT IRREGULARITY 1 0.0001
479 SHOCK 3 0.0001
480 WHITE BLOOD CELL COUNT INCREASED 5 0.0001
481 SEIZURE 15 0.0001
482 PERICARDIAL EFFUSION 3 0.0001
483 HYPOALBUMINAEMIA 1 0.0001
484 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 7 0.0001
485 DRUG-INDUCED LIVER INJURY 4 0.0001
486 TORSADE DE POINTES 1 0.0001
487 CYANOSIS 2 0.0001
488 BLOOD ALBUMIN DECREASED 1 0.0001
489 PRODUCT PRESCRIBING ERROR 3 0.0001
490 RENAL CYST 1 0.0001
491 ULCER 2 0.0001
492 OBESITY 2 0.0001
493 COVID-19 22 0.0001
494 INTENTIONAL OVERDOSE 8 0.0001
495 MIOSIS 1 0.0001
496 SENSORY LOSS 1 0.0001
497 FRUSTRATION TOLERANCE DECREASED 1 0.0001
498 LACTIC ACIDOSIS 4 0.0001
499 MUSCLE TIGHTNESS 2 0.0001
500 POLYURIA 1 0.0001
501 HICCUPS 1 0.0001
502 HAIR DISORDER 1 0.0001
503 ACUTE CORONARY SYNDROME 1 0.0001
504 EMBOLISM 1 0.0001
505 EOSINOPHIL COUNT INCREASED 1 0.0001
506 SYNCOPE 12 0.0001
507 HAEMODIALYSIS 1 0.0001
508 TYPE 2 DIABETES MELLITUS 4 0.0001
509 ANGER 4 0.0001
510 NEUTROPENIA 16 0.0001
511 VITAMIN D DECREASED 1 0.0001
512 PSYCHOLOGICAL TRAUMA 1 0.0001
513 ANHEDONIA 3 0.0001
514 SPINAL OSTEOARTHRITIS 1 0.0001
515 HYPOXIA 4 0.0001
516 THIRST 2 0.0001
517 LOSS OF LIBIDO 1 0.0001
518 OROPHARYNGEAL DISCOMFORT 1 0.0001
519 DRUG EFFECT INCOMPLETE 4 0.0001
520 HYPERGLYCAEMIA 4 0.0001
521 END STAGE RENAL DISEASE 2 0.0001
522 OVARIAN CANCER 1 0.0001
523 TREMOR 18 0.0001
524 RHINORRHOEA 7 0.0001
525 MIDDLE INSOMNIA 2 0.0001
526 LACERATION 1 0.0001
527 INSOMNIA 28 0.0001
528 SINUS BRADYCARDIA 1 0.0001
529 DIZZINESS POSTURAL 1 0.0001
530 HYPOGLYCAEMIA 5 0.0001
531 AUTOIMMUNE DISORDER 1 0.0001
532 VITAMIN D DEFICIENCY 1 0.0001
533 ANXIETY 29 0.0001
534 THERAPY CHANGE 1 0.0001
535 STOMATITIS 6 0.0001
536 FEEDING DISORDER 2 0.0001
537 TASTE DISORDER 2 0.0001
538 EYELID PTOSIS 1 0.0001
539 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 7 0.0001
540 SLUGGISHNESS 1 0.0001
541 VENTRICULAR EXTRASYSTOLES 1 0.0001
542 UNDERDOSE 7 0.0001
543 NERVOUSNESS 5 0.0001
544 INCONTINENCE 1 0.0001
545 BRADYCARDIA 5 0.0001
546 BREAST PAIN 1 0.0001
547 MOVEMENT DISORDER 3 0.0001
548 HYPOACUSIS 4 0.0001
549 PRODUCT USE IN UNAPPROVED INDICATION 23 0.0001
550 DECREASED ACTIVITY 1 0.0001
551 MENTAL DISORDER 4 0.0001
552 CONSTIPATION 20 0.0001
553 OESOPHAGITIS 1 0.0001
554 INTENTIONAL PRODUCT MISUSE 8 0.0001
555 APPLICATION SITE PAIN 2 0.0001
556 STEVENS-JOHNSON SYNDROME 2 0.0001
557 URINARY RETENTION 3 0.0001
558 GAIT INABILITY 3 0.0001
559 MALNUTRITION 1 0.0001
560 ORAL PAIN 2 0.0001
561 THERAPEUTIC PRODUCT EFFECT DECREASED 4 0.0001
562 SKIN INFECTION 1 0.0001
563 NEPHROPATHY TOXIC 1 0.0001
564 THERAPY NON-RESPONDER 4 0.0001
565 BLOOD CALCIUM DECREASED 1 0.0001
566 CONDITION AGGRAVATED 27 0.0001
567 MICTURITION URGENCY 1 0.0001
568 DRUG INEFFECTIVE 115 0.0001
569 NIGHTMARE 3 0.0001
570 CONFUSIONAL STATE 14 0.0001
571 DECREASED APPETITE 20 0.0001
572 ELECTROLYTE IMBALANCE 1 0.0001
573 COGNITIVE DISORDER 4 0.0001
574 HYPERKALAEMIA 3 0.0001
575 OFF LABEL USE 74 0.0001
576 ATAXIA 1 0.0001
577 CHOLECYSTITIS 1 0.0001
578 HYPERLIPIDAEMIA 1 0.0001
579 C-REACTIVE PROTEIN INCREASED 3 0.0001
580 ADRENAL INSUFFICIENCY 1 0.0001
581 NOCTURIA 1 0.0001
582 RESPIRATORY DEPRESSION 1 0.0001
583 GLOMERULAR FILTRATION RATE DECREASED 1 0.0001
584 SMALL INTESTINAL OBSTRUCTION 1 0.0001
585 GENERALISED OEDEMA 1 0.0001
586 CYST 1 0.0001
587 HAIR COLOUR CHANGES 1 0.0001
588 DRUG WITHDRAWAL SYNDROME 7 0.0001
589 DERMATITIS ALLERGIC 1 0.0001
590 CARDIOVASCULAR DISORDER 2 0.0001
591 DIABETES MELLITUS 6 0.0001
592 HYPOPHAGIA 2 0.0001
593 INJECTION SITE INDURATION 1 0.0001
594 DEEP VEIN THROMBOSIS 5 0.0001
595 PLATELET COUNT INCREASED 1 0.0001
596 SARS-COV-2 TEST POSITIVE 1 0.0001
597 HAIR TEXTURE ABNORMAL 1 0.0001
598 QUALITY OF LIFE DECREASED 1 0.0001
599 FEAR 2 0.0001
600 DRY MOUTH 6 0.0001
601 WHITE BLOOD CELL COUNT DECREASED 8 0.0001
602 DYSPHAGIA 7 0.0001
603 TACHYPNOEA 1 0.0001
604 IMPAIRED GASTRIC EMPTYING 1 0.0001
605 PERIPHERAL COLDNESS 1 0.0001
606 HUNGER 1 0.0001
607 WEIGHT DECREASED 20 0.0001
608 SLEEP DISORDER 5 0.0001
609 LYMPHOPENIA 1 0.0001
610 MUSCULAR WEAKNESS 8 0.0001
611 RESPIRATORY FAILURE 5 0.0001
612 DYSPHONIA 4 0.0001
613 PULMONARY MASS 1 0.0001
614 RESPIRATORY DISORDER 2 0.0001
615 PREMATURE BABY 2 0.0001
616 NO ADVERSE EVENT 12 0.0001
617 CORONARY ARTERY DISEASE 2 0.0001
618 LOWER RESPIRATORY TRACT INFECTION 3 0.0001
619 DRUG ADMINISTRATION ERROR 2 0.0001
620 EMOTIONAL DISORDER 2 0.0001
621 GYNAECOMASTIA 2 0.0001
622 EJECTION FRACTION DECREASED 1 0.0001
623 BRAIN FOG 1 0.0001
624 ARRHYTHMIA 3 0.0001
625 BLOOD LACTATE DEHYDROGENASE INCREASED 1 0.0001
626 PNEUMOTHORAX 1 0.0001
627 MOOD SWINGS 2 0.0001
628 OVERDOSE 13 0.0001
629 FACE OEDEMA 1 0.0001
630 METRORRHAGIA 1 0.0001
631 FEELING ABNORMAL 14 0.0001
632 MUSCULOSKELETAL DISCOMFORT 1 0.0001
633 OEDEMA PERIPHERAL 7 0.0001
634 DEVICE USE ISSUE 1 0.0001
635 SYRINGE ISSUE 1 0.0001
636 BURNING SENSATION 4 0.0001
637 COLD SWEAT 1 0.0001
638 LYMPHOCYTE COUNT DECREASED 1 0.0001
639 HEAD DISCOMFORT 1 0.0001
640 ASPARTATE AMINOTRANSFERASE INCREASED 3 0.0001
641 PRODUCT ADHESION ISSUE 2 0.0001
642 WRONG TECHNIQUE IN DRUG USAGE PROCESS 2 0.0001
643 LOSS OF CONSCIOUSNESS 7 0.0001
644 ADVERSE EVENT 5 0.0001
645 MEDICATION ERROR 3 0.0001
646 DYSGEUSIA 4 0.0001
647 HEPATIC STEATOSIS 1 0.0001
648 INTESTINAL OBSTRUCTION 2 0.0001
649 HYPOCALCAEMIA 1 0.0001
650 PULMONARY EMBOLISM 5 0.0001
651 CONVULSION 3 0.0001
652 SLEEP APNOEA SYNDROME 1 0.0001
653 PULMONARY FIBROSIS 1 0.0001
654 ACUTE RESPIRATORY FAILURE 1 0.0001
655 PRESCRIBED OVERDOSE 1 0.0001
656 BLOOD PRESSURE SYSTOLIC INCREASED 1 0.0001
657 CHOKING 1 0.0001
658 HAEMATOCRIT DECREASED 1 0.0001
659 PRESCRIBED UNDERDOSE 1 0.0001
660 BODY TEMPERATURE INCREASED 1 0.0000
661 VOMITING 23 0.0000
662 ALANINE AMINOTRANSFERASE INCREASED 3 0.0000
663 CHEST DISCOMFORT 5 0.0000
664 DRUG DOSE OMISSION 8 0.0000
665 EXPOSURE DURING PREGNANCY 3 0.0000
666 WITHDRAWAL SYNDROME 2 0.0000
667 RENAL IMPAIRMENT 4 0.0000
668 RENAL FAILURE ACUTE 2 0.0000
669 GAIT DISTURBANCE 9 0.0000
670 EATING DISORDER 1 0.0000
671 RETCHING 1 0.0000
672 URINARY TRACT INFECTION 8 0.0000
673 JOINT INJURY 1 0.0000
674 HYPOAESTHESIA 7 0.0000
675 IRRITABLE BOWEL SYNDROME 1 0.0000
676 BALANCE DISORDER 4 0.0000
677 INTERVERTEBRAL DISC PROTRUSION 1 0.0000
678 DEVICE DIFFICULT TO USE 3 0.0000
679 ANGIOEDEMA 2 0.0000
680 LIVER DISORDER 2 0.0000
681 FALL 15 0.0000
682 DEHYDRATION 6 0.0000
683 HEPATIC ENZYME INCREASED 3 0.0000
684 SKIN IRRITATION 2 0.0000
685 NEPHROLITHIASIS 2 0.0000
686 MUSCLE SPASMS 8 0.0000
687 BLOOD GLUCOSE INCREASED 8 0.0000
688 COMA 2 0.0000
689 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 2 0.0000
690 JOINT SWELLING 5 0.0000
691 LIVER INJURY 1 0.0000
692 ENCEPHALOPATHY 1 0.0000
693 BLOOD ALKALINE PHOSPHATASE INCREASED 1 0.0000
694 AGEUSIA 1 0.0000
695 PNEUMONIA ASPIRATION 1 0.0000
696 ABDOMINAL PAIN LOWER 1 0.0000
697 HEPATITIS 1 0.0000
698 HAEMATOMA 1 0.0000
699 DIPLOPIA 1 0.0000
700 RESPIRATORY TRACT INFECTION 1 0.0000
701 GASTRITIS 1 0.0000
702 HYPERTENSION 8 0.0000
703 HYPERSENSITIVITY 7 0.0000
704 MENSTRUATION IRREGULAR 1 0.0000
705 DISTURBANCE IN ATTENTION 2 0.0000
706 FOETAL EXPOSURE DURING PREGNANCY 3 0.0000
707 LIMB INJURY 1 0.0000
708 PRODUCT QUALITY ISSUE 5 0.0000
709 PNEUMONITIS 1 0.0000
710 MEMORY IMPAIRMENT 5 0.0000
711 DIZZINESS 18 0.0000
712 HAEMOPTYSIS 1 0.0000
713 NECK PAIN 2 0.0000
714 ABDOMINAL DISCOMFORT 6 0.0000
715 BLISTER 2 0.0000
716 EYE PAIN 2 0.0000
717 CEREBROVASCULAR ACCIDENT 6 0.0000
718 MULTIPLE ORGAN DYSFUNCTION SYNDROME 1 0.0000
719 PAIN IN JAW 1 0.0000
720 INTENTIONAL DOSE OMISSION 1 0.0000
721 INCORRECT DOSE ADMINISTERED 8 0.0000
722 RED BLOOD CELL COUNT DECREASED 1 0.0000
723 LETHARGY 2 0.0000
724 ASCITES 1 0.0000
725 ACUTE MYOCARDIAL INFARCTION 1 0.0000
726 URINARY INCONTINENCE 1 0.0000
727 ADVERSE DRUG REACTION 3 0.0000
728 BLOOD POTASSIUM DECREASED 1 0.0000
729 HEPATIC FAILURE 1 0.0000
730 CONTRAINDICATED PRODUCT ADMINISTERED 1 0.0000
731 VERTIGO 2 0.0000
732 EPILEPSY 1 0.0000
733 LIMB DISCOMFORT 1 0.0000
734 FEMUR FRACTURE 1 0.0000
735 HEAD INJURY 1 0.0000
736 DRUG INTOLERANCE 3 0.0000
737 NIGHT SWEATS 1 0.0000
738 AMNESIA 2 0.0000
739 BLOOD CREATININE INCREASED 2 0.0000
740 DYSPEPSIA 3 0.0000
741 FEBRILE NEUTROPENIA 2 0.0000
742 VISUAL ACUITY REDUCED 1 0.0000
743 BLOOD PRESSURE DECREASED 2 0.0000
744 EXPIRED PRODUCT ADMINISTERED 1 0.0000
745 SKIN DISORDER 1 0.0000
746 TRANSIENT ISCHAEMIC ATTACK 1 0.0000
747 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 6 0.0000
748 DRUG EXPOSURE DURING PREGNANCY 1 0.0000
749 HAEMOGLOBIN DECREASED 3 0.0000
750 HAEMATURIA 1 0.0000
751 MYOCARDIAL INFARCTION 5 0.0000
752 SYSTEMIC LUPUS ERYTHEMATOSUS 1 0.0000
753 INCORRECT ROUTE OF DRUG ADMINISTRATION 1 0.0000
754 CRYING 1 0.0000
755 PANIC ATTACK 1 0.0000
756 MALAISE 12 0.0000
757 INJECTION SITE MASS 1 0.0000
758 CHEST PAIN 5 0.0000
759 ASTHMA 3 0.0000
760 HOT FLUSH 2 0.0000
761 UNEVALUABLE EVENT 2 0.0000
762 CHRONIC KIDNEY DISEASE 2 0.0000
763 PYREXIA 9 0.0000
764 PARAESTHESIA 4 0.0000
765 COUGH 7 0.0000
766 ABORTION SPONTANEOUS 1 0.0000
767 PSORIATIC ARTHROPATHY 1 0.0000
768 DEVICE BREAKAGE 1 0.0000
769 VISUAL IMPAIRMENT 3 0.0000
770 NAUSEA 19 0.0000
771 RECTAL HAEMORRHAGE 1 0.0000
772 SEPTIC SHOCK 1 0.0000
773 DYSPNOEA 13 0.0000
774 MUSCULOSKELETAL STIFFNESS 2 0.0000
775 MATERNAL EXPOSURE DURING PREGNANCY 2 0.0000
776 DEVICE ISSUE 2 0.0000
777 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 4 0.0000
778 VISION BLURRED 3 0.0000
779 HYPOKALAEMIA 1 0.0000
780 UPPER RESPIRATORY TRACT INFECTION 1 0.0000
781 ABDOMINAL PAIN 5 0.0000
782 BLOOD CHOLESTEROL INCREASED 1 0.0000
783 CARDIAC DISORDER 2 0.0000
784 PRODUCT USE ISSUE 4 0.0000
785 MIGRAINE 2 0.0000
786 BLOOD GLUCOSE DECREASED 1 0.0000
787 RASH 9 0.0000
788 ALOPECIA 4 0.0000
789 DEATH 17 0.0000
790 BLOOD PRESSURE INCREASED 3 0.0000
791 HOSPITALISATION 3 0.0000
792 ABDOMINAL PAIN UPPER 4 0.0000
793 INFLAMMATION 1 0.0000
794 ABDOMINAL DISTENSION 2 0.0000
795 HEADACHE 12 0.0000
796 HAEMORRHAGE 2 0.0000
797 ECZEMA 1 0.0000
798 DERMATITIS ATOPIC 1 0.0000
799 PANCREATITIS 1 0.0000
800 DRUG EFFECT DECREASED 1 0.0000
801 DEPENDENCE 1 0.0000
802 ANAPHYLACTIC REACTION 1 0.0000
803 ARTHROPATHY 1 0.0000
804 MYALGIA 3 0.0000
805 FLATULENCE 1 0.0000
806 EYE IRRITATION 1 0.0000
807 GENERAL PHYSICAL HEALTH DETERIORATION 2 0.0000
808 PALPITATIONS 2 0.0000
809 BONE PAIN 1 0.0000
810 DIARRHOEA 11 0.0000
811 PAIN IN EXTREMITY 5 0.0000
812 DISEASE PROGRESSION 2 0.0000
813 WHEEZING 1 0.0000
814 THERAPEUTIC RESPONSE DECREASED 1 0.0000
815 PLEURAL EFFUSION 1 0.0000
816 DISCOMFORT 1 0.0000
817 FEELING HOT 1 0.0000
818 ANAEMIA 3 0.0000
819 HYPERHIDROSIS 2 0.0000
820 PRODUCT DOSE OMISSION 1 0.0000
821 INJECTION SITE REACTION 1 0.0000
822 THERAPY INTERRUPTED 1 0.0000
823 PRODUCT DOSE OMISSION ISSUE 4 0.0000
824 BRONCHITIS 1 0.0000
825 EPISTAXIS 1 0.0000
826 ACNE 1 0.0000
827 INJECTION SITE SWELLING 1 0.0000
828 CARDIAC FAILURE 1 0.0000
829 CARDIAC FAILURE CONGESTIVE 1 0.0000
830 GASTROOESOPHAGEAL REFLUX DISEASE 1 0.0000
831 PNEUMONIA 4 0.0000
832 GASTROINTESTINAL HAEMORRHAGE 1 0.0000
833 FATIGUE 9 0.0000
834 INTENTIONAL PRODUCT USE ISSUE 1 0.0000
835 GASTROINTESTINAL DISORDER 1 0.0000
836 BREAST CANCER 1 0.0000
837 SWELLING 1 0.0000
838 ASTHENIA 4 0.0000
839 PRURITUS 4 0.0000
840 HEART RATE INCREASED 1 0.0000
841 PAIN 6 0.0000
842 ILLNESS 1 0.0000
843 ACCIDENTAL EXPOSURE TO PRODUCT 1 0.0000
844 ARTHRALGIA 4 0.0000
845 PLATELET COUNT DECREASED 1 0.0000
846 INFLUENZA 1 0.0000
847 SEPSIS 1 0.0000
848 RHEUMATOID ARTHRITIS 1 0.0000
849 BACK PAIN 2 0.0000
850 EMOTIONAL DISTRESS 1 0.0000
851 INJECTION SITE ERYTHEMA 1 0.0000
852 DRY SKIN 1 0.0000
853 PERIPHERAL SWELLING 1 0.0000
854 DRUG DEPENDENCE 1 0.0000
855 URTICARIA 1 0.0000
856 NASOPHARYNGITIS 1 0.0000
857 INJECTION SITE PAIN 1 0.0000